The stroke prevention policy model: Linking evidence and clinical decisions

被引:51
作者
Matchar, DB
Samsa, GP
Matthews, JR
Ancukiewicz, M
Parmigiani, G
Hasselblad, V
Wolf, PA
DAgostino, RB
Lipscomb, J
机构
[1] DUKE UNIV, MED CTR,SCH MED,DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27705 USA
[2] MASSACHUSETTS GEN HOSP, DEPT MED, DIV RADIAT ONCOL, BOSTON, MA 02114 USA
[3] DUKE UNIV, INST STAT & DECIS SCI, DURHAM, NC 27708 USA
[4] BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA
[5] BOSTON UNIV, SCH MED, EVANS MEM DEPT CLIN RES, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA
[6] BOSTON UNIV, COLL ARTS & SCI, DEPT MATH, BOSTON, MA 02215 USA
[7] DUKE UNIV, SANFORD INST PUBL POLICY, DURHAM, NC 27708 USA
[8] BOSTON UNIV, MED CTR, BOSTON, MA USA
关键词
D O I
10.7326/0003-4819-127-8_Part_2-199710151-00054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Simulation models that support decision and cost-effectiveness analysis can further the goals of evidence-based medicine by facilitating the synthesis of information from several sources into a single comprehensive structure. The Stroke Prevention Policy Model (SPPM) performs this function for the clinical and policy questions that surround stroke prevention. This paper first describes the basic structure and functions of the SPPM, concentrating on the role of large databases (broadly defined as any database that contains many patients, regardless of study design) in providing the SPPM inputs. Next, recognizing that the use of modeling continues to be a source of some controversy in the medical community, it; discusses the philosophical underpinnings of the SPPM. Finally, it discusses conclusions in the context of both stroke prevention and other complex medical decisions. We conclude that despite the difficulties in developing comprehensive models (for example, the length and complexity of model development and validation processes, the proprietary nature of data sources, and the necessity for developing new software), the benefits of such models exceed the costs of continuing to rely on more conventional methods. Although they should not replace the clinician in decision making; comprehensive models based on the best available evidence from large databases can support decision making in medicine.
引用
收藏
页码:704 / 711
页数:8
相关论文
共 32 条
[1]  
Beauchamp T., 2009, Principles of biomedical ethics, V6
[2]   COST-EFFECTIVENESS ANALYSIS OF PATIENT-MANAGEMENT ALTERNATIVES AFTER UNCOMPLICATED MYOCARDIAL-INFARCTION - A MODEL [J].
DITTUS, RS ;
ROBERTS, SD ;
ADOLPH, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (04) :869-878
[3]   Is risk neutrality rational? [J].
Douard, J .
MEDICAL DECISION MAKING, 1996, 16 (01) :10-11
[4]  
EDDY DM, 1980, SCREENING CANCER THE
[5]  
FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V21, P482
[6]  
Gold MR, 1996, COST EFFECTIVENESS H, P82
[7]   COMPARISON AND METAANALYSIS OF RANDOMIZED TRIALS OF ENDARTERECTOMY FOR SYMPTOMATIC CAROTID-ARTERY STENOSIS [J].
GOLDSTEIN, LB ;
HASSELBLAD, V ;
MATCHAR, DB ;
MCCRORY, DC .
NEUROLOGY, 1995, 45 (11) :1965-1970
[8]  
IEZZONI LI, 1989, PROVIDING QUALITY CA
[9]  
LAPLACE P, 1952, PHILOS ESSAY PROBABI
[10]   MEDICAL-TREATMENT FOR STROKE PREVENTION [J].
MATCHAR, DB ;
MCCRORY, DC ;
BARNETT, HJM ;
FEUSSNER, JR .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (01) :41-53